No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BLUE240517P7500
- 4.60
- 0.000.00%
15min DelayTrading Dec 8 14:37 ET
0.00High0.00Low
0.00Open4.60Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV203.48%PremiumMay 17, 2024Expiry Date6.54Intrinsic Value100Multiplier-5DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma0.21Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
BLUE Vs. CRSP: Why Are These Stocks Moving in Opposite Directions?
Is Bluebird Bio Stock a Buy?
Express News | Bluebird bio: Sees Significant Changes to Results of Operations for Qtr Ended March 31, 2024 Compared to Corresponding Period Ended in 2023
Express News | Bluebird bio Inc Files for Non-Timely 10-Q With U.S. SEC
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Bluebird Bio (BLUE) and Nuvalent (NUVL)
Bluebird Bio, Inc. (BLUE) Q1 2024 Earnings Call Transcript
bluebird bio, Inc. (BLUE) Q1 2024 Earnings Call Transcript
Comments
$bluebird bio(BLUE.US$ Seems i have majority of posts in this thread since beginning of year! Hehehe! But im going to give one more! IMO from the latest update and from the earnings call! ( Which I recommend you read the earnings call transcript ) I see earnings from this company just getting better and better! IMO im looking for it to just keep growing going forward! And if you read the transcript? Im sure you to will see why i say this. Happy reading![]()
4
2
$bluebird bio(BLUE.US$ Reuters· 1 min ago
Bluebird bio Inc - Anticipates Recognizing Revenue From Its First Infusion of Lyfgenia in Q3 of 2024
Bluebird bio Inc - Anticipates Recognizing Revenue From Its First Infusion of Lyfgenia in Q3 of 2024
1
$bluebird bio(BLUE.US$ Bluebird bio Announces Completion of First Cell Collection for Lyfgenia™ Gene Therapy
$bluebird bio(BLUE.US$ Watching Bluebird Bio; Shares Spike Higher As Traders Circulating Unconfirmed Rumor Suggesting "Lyfgenia Is Among 8 New Therapies In The Running To Receive NTAP Designations At The Start Of FY25. The Emphasis On Supporting Access For SCD Therapies Across HHS Leaves Little Doubt That The New Therapy Will Qualify"
4
2
Read more
JCBF : Seems like more time is needed but heading on the right path to getting patients in line. They seem optimistic as far as the company goes. I'm sure there's a lot of bureaucracy and red tape to getting payments. Like anything else, it should get easier as they go or as they set precedent, so it seems. Not all QTC's are equal and interesting some don't want to be listed on their website though. Wonder if that's a product thing or just not in need of an another patient. Either way, appreciate ya pointing this out. Will be keeping eye on this one too.
TrytosaveabitOP JCBF: You’re very welcome! Where ya been. I was thinking wow his work musta really picked up. Well at least I’m hoping it was that and nothings gone bad! Anyways good to see ya